SOUTH SAN FRANCISCO, Calif.,
Nov. 19, 2020 /PRNewswire/ -- Pliant
Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biopharmaceutical company focused on discovering and developing
novel therapies for the treatment of fibrosis, today announced its
participation in the Piper Sandler 32nd Annual Healthcare
Conference to be held virtually December
1 – 3, 2020.
Bernard Coulie, M.D., Ph.D.,
president and chief executive officer of Pliant Therapeutics, will
participate in a fireside chat with Tyler
M. Van Buren, senior biotechnology analyst at Piper Sandler.
The fireside chat will be pre-recorded and available beginning on
Monday, November 23, 2020 at
10:00 am ET by visiting the "News
& Events" section of the "Investors & Media" page of the
Pliant Therapeutics' website at www.pliantrx.com.
The webcast replay of the fireside chat will be archived for 90
days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant
Therapeutics is a clinical stage biopharmaceutical company
focused on discovering and developing novel therapies for the
treatment of fibrosis. Pliant's lead product candidate, PLN-74809,
is an oral small-molecule dual selective inhibitor of
avß6 and avß1 integrins
that is in development for the treatment of idiopathic pulmonary
fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
PLN-74809 has received Orphan Drug Designation from the U.S.
Food and Drug Administration for both IPF and PSC. Pliant is
currently recruiting Phase 2a trials of PLN-74809 for the treatment
of IPF and PSC. Pliant's second product candidate, PLN-1474, is a
small-molecule selective inhibitor of avß1
for the treatment of liver fibrosis associated with nonalcoholic
steatohepatitis, or NASH, which Pliant has partnered with Novartis.
PLN-1474 is currently undergoing a Phase 1 trial. In addition to
clinical stage programs, Pliant currently has two preclinical
programs targeting oncology and muscular dystrophies. For
additional information about Pliant Therapeutics, visit
www.pliantrx.com and follow us on Twitter, LinkedIn, and
Facebook.
Investor Contact:
Christopher
Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
Media Contact:
Cambria Fuqua
Canale Communications
cambria.fuqua@canalecomm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301176485.html
SOURCE Pliant Therapeutics, Inc.